The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems
Open accessAbstract
Conventional chemotherapy lacking target selectivity often leads to severe side effects, limiting the effectiveness of chemotherapy. Therefore, drug delivery systems ensuring both selective drug release and efficient intracellular uptake at the target sites are highly demanded in chemotherapy to improve the quality of life of patients with low toxicity. One of the effective approaches for tumor-selective drug delivery is the adoption of functional ligands that can interact with specific receptors overexpressed in malignant cancer cells. Various functional ligands including folic acid, hyaluronic acid, transferrin, peptides, and antibodies, have been extensively explored to develop tumor-selective drug delivery systems. Furthermore, cell-penetrating peptides or ligands for tight junction opening are also actively pursued to improve the intracellular trafficking of anticancer drugs. Sometimes, multiple ligands with different roles are used in combination to enhance the cellular uptake as well as target selectivity of anticancer drugs. In this review, the current status of various functional ligands applicable to improve the effectiveness of cancer chemotherapy is overviewed with a focus on their roles, characteristics, and preclinical/clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
One-Carbon Metabolism in Health and Disease
Ducker, G. S., & Rabinowitz, J. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.009 · Cited by 2,239 · cited 1×
“As mammals are unable to synthesize folate by themselves, it has to be derived entirely from dietary sources (Ducker & Rabinowitz, 2017).”
BackgroundTumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262 · cited 2×
“This is popularly referred to as the enhanced permeability and retention (EPR) effect and is exploited in the treatment of diverse tumors (Golombek et al., 2018).”
BackgroundHypoxia and Metabolic Adaptation of Cancer Cells
Eales, K. L., Hollinshead, K. E. R., & Tennant, D. A. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.50 · Cited by 724 · cited 1×
“In particular, FR-α isoform has a high affinity to FA (Kd 1 0 −9 M) (Chandrupatla et al., 2019), which is crucial for tumor tissues to sustain their speedy and uncontrolled proliferation (Eales et al., 2016).”
BackgroundRecent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623
Muhamad, N., Plengsuriyakarn, T., & Na-Bangchang, K. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s165210 · Cited by 410
Anderson, G. J., & Vulpe, C. D. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0051-1 · Cited by 317 · cited 1×
“TfR1 is able to internalize two Tf via TfR-mediated endocytosis (Anderson & Vulpe, 2009).”
BackgroundLv, Y., Xu, C., Zhao, X., Lin, C., Yang, X., Xin, X., Zhang, L., Qin, C., Han, X., Yang, L., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b08051 · Cited by 235
An updated review of folate-functionalized nanocarriers: A promising ligand in cancer
Ebrahimnejad, P., Sodagar Taleghani, A., Asare-Addo, K., & Nokhodchi, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.011 · Cited by 133 · cited 1×
“More details are well covered in previous reviews (Narmani et al., 2019; Ebrahimnejad et al., 2022).”
Cited by
PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy
Kesharwani, P., Kumar, V., Goh, K. W., Gupta, G., Alsayari, A., Wahab, S., & Sahebkar, A. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02410-x · Cited by 132
“Furthermore, targeted drug delivery can be achieved by adding specific ligands to PLGA nanoparticles, such as antibodies or peptides [66].”
Tiwari, P., Yadav, K., Shukla, R. P., Gautam, S., Marwaha, D., Sharma, M., & Mishra, P. R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.016 · Cited by 88
Metadata
- Authors
- Bajracharya, R., Song, J. G., Patil, B. R., Lee, S. H., Noh, H.-M., Kim, D.-H., Kim, G.-L., Seo, S.-H., Park, J.-W., Jeong, S. H., Lee, C. H., & Han, H.-K.
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2022-06-28
- Volume
- 29
- Issue
- 1
- Pages
- 1959-1970
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W4283657702
- Cited by
- 246
- References
- 8
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. https://app.cochat.ai/papers/10.1080/10717544.2022.2089296
- The paper
- Bajracharya, R., Song, J. G., Patil, B. R., Lee, S. H., Noh, H.-M., Kim, D.-H., Kim, G.-L., Seo, S.-H., Park, J.-W., Jeong, S. H., Lee, C. H., & Han, H.-K. (2022). Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Delivery. https://doi.org/10.1080/10717544.2022.2089296
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.